1. Home
  2. NI vs ILMN Comparison

NI vs ILMN Comparison

Compare NI & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NiSource Inc

NI

NiSource Inc

HOLD

Current Price

$47.23

Market Cap

22.5B

Sector

Utilities

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$118.54

Market Cap

20.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NI
ILMN
Founded
1912
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Medical Specialities
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.5B
20.4B
IPO Year
2018
2000

Fundamental Metrics

Financial Performance
Metric
NI
ILMN
Price
$47.23
$118.54
Analyst Decision
Buy
Hold
Analyst Count
10
17
Target Price
$47.50
$124.24
AVG Volume (30 Days)
3.7M
1.9M
Earning Date
05-13-2026
04-30-2026
Dividend Yield
2.57%
N/A
EPS Growth
20.37
170.87
EPS
1.95
5.45
Revenue
N/A
$4,343,000,000.00
Revenue This Year
$3.28
$6.52
Revenue Next Year
$4.97
$5.49
P/E Ratio
$23.93
$21.19
Revenue Growth
N/A
N/A
52 Week Low
$36.86
$68.70
52 Week High
$47.67
$155.53

Technical Indicators

Market Signals
Indicator
NI
ILMN
Relative Strength Index (RSI) 60.21 40.20
Support Level $42.69 $114.88
Resistance Level N/A $135.68
Average True Range (ATR) 0.93 4.53
MACD -0.10 -0.34
Stochastic Oscillator 84.78 19.13

Price Performance

Historical Comparison
NI
ILMN

About NI NiSource Inc

NiSource is one of the nation's largest natural gas distribution companies with 3.2 million customers in Indiana, Kentucky, Maryland, Ohio, Pennsylvania, and Virginia. NiSource's electric utility transmits and distributes electricity in northern Indiana to about 500,000 customers. The regulated electric utility also owns more than 3,000 megawatts of generation capacity, including coal, natural gas, and renewable energy.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: